// App-Quantinova.ai

: First-Line Consolidation Therapy with CD19/CD22 Bispecific CAR-T Cells for MRD Positive B-ALL Maybe Feasible

Researchers

Presenter

  • Xianmin Song

Principal Investigators

  • N/A

Medical Centers

  • Department of Hematology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, shanghai, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • B-cell acute lymphoblastic leukemia

  • Cytokine release syndrome

  • Anemia

Biomarkers

  • Cluster of Differentiation 19

  • Cytokine

  • Twist-related protein 1

Drug/Treatment

  • Prednisone

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved